
# A Case of Major Depressive Disorder in an adolescent patient exacerbated by Montelukast

Samuel Polhemus MD; Samantha Fleck MD; Christopher Rogers MD

Following post-market reports of increased neuropsychiatric events of Montelukast, the FDA issued a black box warning in March of 2020.<sup>1</sup> This black box warning has since been studied and there have been mixed results between various publications. Many studies have demonstrated a strong correlation between Montelukast and recommend caution/monitoring for neuropsychiatric effects.<sup>2–4</sup> Some studies have demonstrated that this correlation is not as strong as some research suggests and that there may not be any increased risk of suicide as well.<sup>5–8</sup> Although the mechanism of action is not entirely understood, one study theorized that the mechanism behind this is that Montelukast interferes with glutathione detoxification and interacts with neurotransmitter/neurosteroids in the HPA axis.<sup>9</sup> Due to the conflicting evidence and relatively recent issuing of the black box warning in 2020 this case report is necessary to bring to light an example of an adolescent patient who was having significant depressive symptoms suspected to be worsened by Montelukast and improved significantly when it was discontinued.



Margues et al.

This research was supported (in whole or in part) by HCA Healthcare and/or an HCA Healthcare affiliated entity. The views expressed in this publication represent those of the author(s) and do not necessarily represent the official views of HCA Healthcare or any of its affiliated entities.

## Background

2020-2021:

- With the isolation due to COVID and transition to online school parents noted an onset of depressive symptoms during this time more irritability
- At this time patient was 13 years old
- March of this time patient was brought by his parents to the pediatrician and was started on Fluoxetine. 2021

• Due to concerns for patient's ongoing allergic rhinitis/asthma symptoms he was started at this time on Montelukast; per parents report they were not informed of black box warning 2021-2022:

- After a brief symptom remission, his mood symptoms returned and persisted for the following year despite increases in Fluoxetine 2023:
- Patient continues to have severe mood symptoms, but no hospitalizations or suicide attempts. Consistently low mood and depressive symptoms

• During this time he was switched to Escitalopram 2023:

 Patient is transferred to a psychiatric NP and was placed on Aripiprazole and Bupropion XR; Escitalopram discontinued

• He continues to demonstrate consistent depressive symptoms 2023:

• ER visit for a Panic attack and severe depression with SI September 2023:

Started IOP

- 2023:
- He is transferred to the outpatient clinic where first author initiated care of patient
- At that time he was on Aripiprazole 5mg daily as well as Bupropion extended release 150mg
- Initial treatment plan was to initiate psychotherapy and discontinue did not seem appropriate yet

 Bupropion increased to 300mg 2023:

- Despite increase in Bupropion symptoms continue; initial plan was medications; parents were informed to contact pediatrician and request alternative agent to see if Montelukast was exacerbating symptoms
- Within 3 days of discontinuing Montelukast patient demonstrated as well as observed behaviors by parents 2023:
- Patient continuing to demonstrate symptom remission despite no further changes in medications after stopping montelukast



### Case

including more isolation, less socialization with the family/peers, and

abilify as bupropion had not been properly titrated and augmentation

to continue medication for two more weeks, but parents called the day after the appointment and were curious about Montelukast and neuropsychiatric black box warning they found while researching his

significant improvements in both subjective, self-reported symptoms

Discussion

Although this patient's case is still ongoing, his significant improvement regarding his self-reported depression symptoms as well as observed behaviors at home within 3 days after discontinuation is suspicious for at least an exacerbating effect by montelukast. The pharmacokinetics of montelukast demonstrate a short half-life (approx. 4.5 hours) but given the suspicion for cause via metabolites it is difficult to know for certain how impactful montelukast was.<sup>9,10</sup> This report is also limited by the history and symptoms being almost exclusively self-report by the patient and his parents. He is still being seen in the outpatient clinic and the plan is to taper Bupropion extended release to see if symptoms remain in remission without any medication treatment. Other considerations for his diagnosis and confounding variables are hypothyroidism/organic depression which was not seen on labs. Additionally there may have been a placebo-effect of stopping montelukast as well as the possible benefit of increasing Wellbutrin; however, the rapid and significant nature of his symptom improvement is inconsistent with the usual onset time of Wellbutrin and placebo would unlikely lead to sustained remission

### Conclusion

Providers should be asking about neuropsychiatric side effects after the initiation of montelukast and psychiatric prescribers should be aware to monitor for patients on Montelukast. It is worth considering discontinuation of montelukast in children and adolescents presenting with new-onset psychiatric symptoms or worsening and treatment resistance of pre-existing symptoms. More research is needed into the risk of this reaction occurring as well as the pathophysiology that may be causing it.

### References

Abdelkader S, Hendrix-Dicken AD, Condren M. The Impact of Montelukast's Black Box Warning on Pediatric Mental Health Adverse Event Reports. J Pediatr Pharmacol Ther. 2023;28(8):704-709. doi:10.5863/1551-6776-28.8.704

Jordan A, Toennesen LL, Eklöf J, et al. Psychiatric Adverse Effects of Montelukast-A Nationwide Cohort Study. J Allergy Clin Immunol Pract. 2023;11(7):2096-2103.e1. doi:10.1016/j.jaip.2023.03.010

Al-Shamrani A, Alharbi S, Kobeisy S, et al. Adverse Drug Reactions (ADRs) of Montelukast in Children. Children (Basel). 2022;9(11):1783. doi:10.3390/children9111783

Paljarvi T, Forton J, Luciano S, Herttua K, Fazel S. Analysis of Neuropsychiatric Diagnoses After Montelukast Initiation. JAMA Netw Open. 2022;5(5):e2213643. doi:10.1001/jamanetworkopen.2022.13643 Mou Y, Song Q, Zhao C, Fang H, Ren C, Song X. Meta-analysis of the relationship between

montelukast use and neuropsychiatric events in patients with allergic airway disease. *Heliyon*. 2023;9(11):e21842. doi:10.1016/j.heliyon.2023.e21842

Fox CW, Khaw CL, Gerke AK, Lund BC. Montelukast and neuropsychiatric events - a sequence symmetry analysis. J Asthma. 2022;59(12):2360-2366. doi:10.1080/02770903.2021.2018705

Lo CWH, Pathadka S, Qin SX, et al. Neuropsychiatric events associated with montelukast in patients with asthma: a systematic review. *Eur Respir Rev.* 2023;32(169):230079. doi:10.1183/16000617.0079-2023

Schumock GT, Stayner LT, Valuck RJ, Joo MJ, Gibbons RD, Lee TA. Risk of suicide attempt in asthmatic children and young adults prescribed leukotriene-modifying agents: a nested case-control study. J Allergy Clin Immunol. 2012;130(2):368-375. doi:10.1016/j.jaci.2012.04.035

Marques CF, Marques MM, Justino GC. The mechanisms underlying montelukast's neuropsychiatric effects - new insights from a combined metabolic and multiomics approach. *Life Sci.* 2022;310:121056. doi:10.1016/j.lfs.2022.121056

Cheng H, Leff JA, Amin R, et al. Pharmacokinetics, bioavailability, and safety of montelukast sodium (MK-0476) in healthy males and females. *Pharm Res.* 1996;13(3):445-448. doi:10.1023/a:1016056912698

